TXMD Quote, Financials, Valuation and Earnings

Amgen, Inc. has a net margin of 6.38% compared to TherapeuticsMD, Inc.'s net margin of 33.55%. TherapeuticsMD, Inc.'s return on equity of 0.27% beat Amgen, Inc.'s return on equity of 95.55%.

TherapeuticsMD, Inc. has a consensus price target of --, signalling upside risk potential of 194.12%. On the other hand Amgen, Inc. has an analysts' consensus of $325.88 which suggests that it could fall by -0.46%. Given that TherapeuticsMD, Inc. has higher upside potential than Amgen, Inc., analysts believe TherapeuticsMD, Inc. is more attractive than Amgen, Inc..

TherapeuticsMD, Inc. has a beta of 0.414, which suggesting that the stock is 58.639% less volatile than S&P 500. In comparison Amgen, Inc. has a beta of 0.451, suggesting its less volatile than the S&P 500 by 54.893%.

TherapeuticsMD, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen, Inc. offers a yield of 2.91% to investors and pays a quarterly dividend of $2.38 per share. TherapeuticsMD, Inc. pays -- of its earnings as a dividend. Amgen, Inc. pays out 119.05% of its earnings as a dividend.

TherapeuticsMD, Inc. quarterly revenues are $784K, which are smaller than Amgen, Inc. quarterly revenues of $9.6B. TherapeuticsMD, Inc.'s net income of $50K is lower than Amgen, Inc.'s net income of $3.2B. Notably, TherapeuticsMD, Inc.'s price-to-earnings ratio is 65.38x while Amgen, Inc.'s PE ratio is 25.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TherapeuticsMD, Inc. is 7.03x versus 4.94x for Amgen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of 6.38% compared to TherapeuticsMD, Inc.'s net margin of 31.72%. TherapeuticsMD, Inc.'s return on equity of 0.27% beat Eli Lilly & Co.'s return on equity of 106.26%.

TherapeuticsMD, Inc. has a consensus price target of --, signalling upside risk potential of 194.12%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,093.22 which suggests that it could grow by 2.03%. Given that TherapeuticsMD, Inc. has higher upside potential than Eli Lilly & Co., analysts believe TherapeuticsMD, Inc. is more attractive than Eli Lilly & Co..

TherapeuticsMD, Inc. has a beta of 0.414, which suggesting that the stock is 58.639% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

TherapeuticsMD, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.56% to investors and pays a quarterly dividend of $1.50 per share. TherapeuticsMD, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

TherapeuticsMD, Inc. quarterly revenues are $784K, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. TherapeuticsMD, Inc.'s net income of $50K is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, TherapeuticsMD, Inc.'s price-to-earnings ratio is 65.38x while Eli Lilly & Co.'s PE ratio is 52.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TherapeuticsMD, Inc. is 7.03x versus 16.44x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of 6.38% compared to TherapeuticsMD, Inc.'s net margin of -255.85%. TherapeuticsMD, Inc.'s return on equity of 0.27% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

TherapeuticsMD, Inc. has a consensus price target of --, signalling upside risk potential of 194.12%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -83.96%. Given that TherapeuticsMD, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe TherapeuticsMD, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

TherapeuticsMD, Inc. has a beta of 0.414, which suggesting that the stock is 58.639% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

TherapeuticsMD, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. TherapeuticsMD, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

TherapeuticsMD, Inc. quarterly revenues are $784K, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. TherapeuticsMD, Inc.'s net income of $50K is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, TherapeuticsMD, Inc.'s price-to-earnings ratio is 65.38x while NovaBay Pharmaceuticals, Inc.'s PE ratio is 8.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TherapeuticsMD, Inc. is 7.03x versus 10.30x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of 6.38% compared to TherapeuticsMD, Inc.'s net margin of 21.32%. TherapeuticsMD, Inc.'s return on equity of 0.27% beat Pfizer Inc.'s return on equity of 10.84%.

TherapeuticsMD, Inc. has a consensus price target of --, signalling upside risk potential of 194.12%. On the other hand Pfizer Inc. has an analysts' consensus of $28.62 which suggests that it could grow by 13.63%. Given that TherapeuticsMD, Inc. has higher upside potential than Pfizer Inc., analysts believe TherapeuticsMD, Inc. is more attractive than Pfizer Inc..

TherapeuticsMD, Inc. has a beta of 0.414, which suggesting that the stock is 58.639% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

TherapeuticsMD, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.83% to investors and pays a quarterly dividend of $0.43 per share. TherapeuticsMD, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

TherapeuticsMD, Inc. quarterly revenues are $784K, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. TherapeuticsMD, Inc.'s net income of $50K is lower than Pfizer Inc.'s net income of $3.6B. Notably, TherapeuticsMD, Inc.'s price-to-earnings ratio is 65.38x while Pfizer Inc.'s PE ratio is 14.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TherapeuticsMD, Inc. is 7.03x versus 2.29x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.